You are here: Industry Insights > antibody

News List

Scientists identified vulnerable site on multiple coronaviruses WorldPharmaNews
February 11, 2022
The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research.
New Covid-19 treatment drug available for use in Ireland FirstWordPharma
January 28, 2022
Ireland has agreed a supply deal for GlaxoSmithKline's COVID-19 antibody treatment Xevudy (sotrovimab), reported The Irish Times.
Feds may limit authorizating monoclonal antibody treatments FirstWordPharma
January 24, 2022
According to a source familiar with the decision-making, US regulators are considering limiting the authorization of certain monoclonal antibody treatments for COVID-19 that have not proved effective against the Omicron variant, reported CNN.
ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX? Technology B3Cnewswire
January 14, 2022
ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.
ABL Bio and Sanofi partner to develop antibody for Parkinson’s disease Pharmaceutical-Technology
January 13, 2022
ABL Bio will receive $985m in milestone payments from Sanofi in addition to royalties on the net sales of the product.
Twist-Revelar’s therapy neutralises Omicron and Delta variants Pharmaceutical-Technology
January 07, 2022
Twist Bioscience and Revelar Biotherapeutics have reported data from live virus studies where their therapy, RBT-0813, showed it binds to and neutralises SARS-CoV-2 Omicron and Delta variants.
BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment FirstWordPharma
December 30, 2021
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses...
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors prnasia
December 28, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation...
Valneva Announces Positive Booster Data for COVID Vax Candidate contractpharma
December 17, 2021
Valneva SE announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 Vaccine candidate, VLA2001.
Evusheld Long-Acting Antibody Combination Retains Neutralizing Activity Against Omicron Variant in Independent FDA Study AmericanPharmaceuticalReview
December 17, 2021
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.